RE:RE:RE:The Parade!"I will repeat once again. The fact that the trial is currently only ~2/3rds full after seven months of aquiring test participants is not 'just an opinion'. It is fact" I will repeat it once again.....no one here believes this to be fact. And even though I have asked your on numerous occassion....with the word 'please'.....
you refused to tell us where you got this information that contradicts the companies press release of August.
Back in August the company anticipated a small delay....in advance....and issued a press release stating such. With patient complition news anticipated now within weeks and the company has not felt a need to issue another revision, we can safely assume that everything is on schedule.
So why should we believe an anonymous poster who refuses to answer the very simple and basic question......"where did you get your information"? Until you do so....your information remains
non-factual, due to your stubbornness.
HailMary wrote:
I will repeat once again. The fact that the trial is currently only ~2/3rds full after seven months of aquiring test participants is not 'just an opinion'. It is fact. Choose to ignore that, well that's your option. I have no ulterior motive. And don't worry, I'm not after your shares!!!
I am not saying the trial won't be finish at some point in the future, nor am I saying that Ph 2b won't be successful. I actually believe it will. Alomost all Ph 2b trials are successful as they are just accessing dose ranges. But it is in a lengthy delay here and they are having trouble finding participants that fit the rather stringent criteria that was laid out.
I came looking for a group suggestion for a proposed timeline based on my recent findings. I egt that it threatens your positions in this company, but that's nothing new by the sounds of it.
So until I learn otherwise, I do belive my projected timeline will hold true. The largest variable being, just how long to actually compile and release the test results once completed next year.
One area that we will disagree on I'm sure. I am not confident that the drug ever gets to market. Odds are stacked against ATE, with only 1/5000 new drugs ever getting that far. Phase 3 will involve 2000-3000 participants, will take upwards of 2-3 years to complete, and is going to cost a lot of money. Most of that many will be raised off the backs of current shareholders thru more dilution, and with any luck, some assistance from a future partner.